期刊
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
卷 7, 期 2, 页码 137-145出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2014.889563
关键词
antidepressant; F2695; levomilnacipran; major depressive disorder; serotonin and norepinephrine; reuptake inhibitors
资金
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly and Company
- Forest Research Institute
- GlaxoSmithKline
- Otsuka Pharmaceutical Development & Commercialization, Inc
- Shire Development, LLC
- Genomind
- Forest Laboratories
- Bristol-Myers Squibb Company
- Cerecor, Inc.
- Eli Lilly Co.
- Dey Pharma
- L.P., Forest Laboratories
- Gerson Lehman Group
- Guidepoint Global
- H. Lundbeck A/S
- MedAvante, Inc.
- Merck and Co. Inc.
- Neuronetics, Inc.
- Novartis
- Otsuka
- Ortho-McNeil Pharmaceuticals
- Pamlab, L.L.C.
- Pfizer
- PGx, Inc
- Shire US Inc.
- Sunovion Pharmaceuticals, Inc.
- Supernus Pharmaceuticals
- Takeda and Transcept Pharmaceuticals
- Agency for Healthcare Research and Quality, Alkermes
- Forest Pharmaceuticals
- National Institute of Mental Health
- Otsuka Pharmaceuticals
- PharmaNeuroboost
- Roche
Levomilnacipran is a novel serotonin and norepinephrine reuptake inhibitor (SNRI) for the treatment of major depressive disorder. This paper reviews up-to-date data on the pharmacology, short- and long-term efficacy, safety and tolerability of levomilnacipran. The drug differs from previously available SNRIs in having twice the potency for norepinephrine versus serotonin reuptake inhibition. In four of the six short-term clinical trials, levomilnacipran was statistically significantly more efficacious than placebo. The only available relapse prevention study did not show reduction in time to relapse, perhaps because relapse rates were low. The commonest adverse events occurring twice as often as on placebo were nausea, hyperhidrosis, constipation, tachycardia, vomiting, erectile dysfunction, palpitations, and ejaculation disorder. In a few patients, hypertension or orthostatic hypotension may occur. Levomilnacipran has been shown to be effective in the short-term treatment of major depressive disorder and may represent an incremental advance. However, further research about its efficacy in subgroups of patients and comparing it to other antidepressants is needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据